RALLYBIO CORPORATION Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
RALLYBIO CORPORATION (RLYB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $8.56 per share for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-26
- RALLYBIO CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $6.08.
- RALLYBIO CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00.
- RALLYBIO CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.00.
- RALLYBIO CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00.
- RALLYBIO CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.00.
- RALLYBIO CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- RALLYBIO CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $10.38.
- RALLYBIO CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $0.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.56 S-4/A · filed 2026-08-26 | |||
| 2026-03-31 | $6.08 S-4 · filed 2026-07-15 | |||
| 2025-12-31 | $0.00 S-4/A · filed 2026-08-26 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-03-13 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $0.00 10-K · filed 2024-03-12 | |||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $10.38 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $10.38 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $0.00 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |